Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus apatinib in stage IV KRAS-mutant non-squamous non-small cell lung cancer
CTR20190113Phase 2Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Sep 2019; status: terminated.
02
Drugs
camrelizumabRivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20190113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190113.